Galapagos Revenue 2013-2021 | GLPG

Galapagos revenue from 2013 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Galapagos Annual Revenue
(Millions of US $)
2020 $606
2019 $1,003
2018 $375
2017 $176
2016 $168
2015 $67
2014 $120
2013 $212
2012 $197
Galapagos Quarterly Revenue
(Millions of US $)
2021-06-30 $184
2021-03-31 $150
2020-12-31 $190
2020-09-30 $168
2020-06-30 $130
2020-03-31 $118
2019-12-31 $165
2019-09-30 $716
2019-06-30 $76
2019-03-31 $46
2018-12-31 $132
2018-09-30 $120
2018-06-30 $68
2018-03-31 $55
2017-09-30
2017-03-31 $44
2016-03-31 $16
2015-12-31 $15
2015-09-30 $11
2015-06-30 $19
2015-03-31 $23
2014-12-31
2014-06-30
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.507B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00